

### Supplementary table. Main study results

Infants who started the oral immunotherapy protocol, number (%)	68 (100%)
Infants who reached the target of the protocol, number (%)	66 (97%)
Time to reach the target of the protocol in months, median (IQR and range)	5.5 (IQR 4.5-7, range 3.5-16).
Infants who experienced at least an allergic reactions in hospital, number (%)	7 (10%)
<p>Allergic reactions recorded in hospital, number.</p> <p>Severity of reactions, number:</p> <ul style="list-style-type: none"> <li>- class 1 (localized cutaneous erythema/urticaria/angioedema/oral pruritus)</li> <li>- class 2 (generalised erythema/urticaria/angioedema)</li> <li>- class 3 (at least 1 or 2 plus gastrointestinal symptoms/rhinoconjunctivitis)</li> </ul>	<p>13</p> <p>8</p> <p>4</p> <p>1</p>
Infants who experienced at least an allergic reaction at home, number (%)	29 (43%)
Allergic reactions recorded at home, number.	40

Severity of reactions, number:	
- class 1 (localized cutaneous erythema/urticaria/angioedema/oral pruritus)	35
- class 2 (generalised erythema/urticaria/angioedema)	3
- class 3 (at least 1 or 2 plus gastrointestinal symptoms/rhinoconjunctivitis)	2